The Lysine Specific Histone Demethylase 1A pipeline drugs market research report outlays comprehensive information on the Lysine Specific Histone Demethylase 1A targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Lysine Specific Histone Demethylase 1A pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Hematological Disorders, Central Nervous System, and Infectious Disease which include the indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Small-Cell Lung Cancer, Sickle Cell Disease, Thalassemia, Central Nervous System, Alzheimer’s Disease, Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, and Coronavirus Disease 2019 (COVID-19) Pneumonia. It also reviews key players involved in Lysine Specific Histone Demethylase 1A targeted therapeutics development with respective active and dormant or discontinued products.
The Lysine Specific Histone Demethylase 1A pipeline targets constitutes close to 35 molecules. Out of which, approximately 27 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 1, 4, 2, 15, and 5 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 4, and 4 molecule.
Lysine Specific Histone Demethylase 1A overview
Lysine-specific histone demethylase 1A (KDM1A) also known as lysine (K)-specific demethylase 1A (LSD1) is a protein in encoded by the KDM1A gene. LSD1 specifically demethylates mono- or dimethylated dimethylated histone H3 lysine4 (H3K4) and H3 lysine 9 (H3K9) via a redox process. LSD1 played an important role in a broad spectrum of biological processes, including cell proliferation, adipogenesis, spermatogenesis, chromosome segregation and embryonic development.
For a complete picture of Lysine Specific Histone Demethylase 1A’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
